Familial adenomatous polyposis (FAP) is an inherited disorder characterized by the early onset of multiple adenomatous polyps in the colon and rectum. Unless the colon is removed, most patients with ...

Familial adenomatous polyposis is caused by abnormalities in the APC gene. The Food and Drug Administration (FDA) has granted Fast Track designation to REC-4881 for the treatment of familial ...

Familial adenomatous polyposis (FAP) is caused by mutations in the APC gene and 2 different, or biallelic mutations, in the MUTYH gene. However, not all patients with colorectal polyposis are found to ...

Please provide your email address to receive an email when new articles are posted on . For patients with familial adenomatous polyposis, incidence of disease progression was not significantly lower ...

Use of the epidermal growth-factor receptor inhibitor erlotinib led to about a 30% reduction in duodenal polyp burden after 6 months of once-weekly treatment for patients with familial adenomatous ...

Familial adenomatous polyposis is an inherited condition that significantly increases the risk for colon cancer. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TPST-1495 ...

Familial adenomatous polyposis coli (FAP) has been shown to be associated with germline mutations of the adenomatous polyposis gene (APC) on chromosome 5. Extra-colonic manifestations also occur in ...

Familial adenomatous polyposis (FAP) is a hereditary disease which, in addition to a high risk of bowel cancer, also a greatly increased risk of duodenal cancer. At present, the only treatment ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Celecoxib reduced event rate and delayed progression of adenomas in children with familial ...

Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (BDRX), a clinical stage ...

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona Biodexa Pharmaceuticals PLC, ...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 15, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) announced today that its licensee Janssen Research & Development, LLC ...